By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TargeGen, Inc. 

9380 Judicial Drive

San Diego  California  92121  U.S.A.
Phone: 858-678-0760 Fax: 858-678-0762


SEARCH JOBS

TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego. The company develops small molecule multi-target kinase inhibitors and combines a focus on vascular biology with expertise in small molecule medicinal chemistry. TargeGen compounds are primarily designed to inhibit vascular permeability, vascular proliferation, and inflammation. These biological processes are common to the pathology of many major human diseases. TargeGen's current compound in clinical development is TG101348 for the treatment of myeloproliferative diseases. The company has additional compounds in development for the treatment of inflammatory and ocular diseases.

TargeGen Drug Discovery
TargeGen's proprietary compounds are designed using advanced rational design techniques aided by computational chemistry and modeling technologies. TargeGen discovery programs are primarily focused on the development of src-kinase, PI3K and Jak-2 inhibitors.

TargeGen Investors Include:

  • Forward Ventures
  • VantagePoint Venture Partners
  • Enterprise Partners
  • William Blair Capital Partners/Chicago Growth Partners
  • CDP Capital
  • BB BIOTECH VENTURES
  • Hambrecht & Quist Capital Management
  • Innovis Investments
  • A.M. Pappas & Associates
  • CTI Life Sciences Fund


Key Statistics


Email: info@targegen.com
Ownership: Private

Web Site: TargeGen, Inc.
Employees:
Symbol: 
 





Collaborations

CyDex, Inc.  Licensing Agreement

Merck KGaA  Licensing Agreement - Vascular Biology Portfolio.





Company News
Sanofi-Aventis (France) (SASY.PA) Agrees to Acquire TargeGen, Inc. for $75 Million Upfront; May Spend as Much as $560 Million on Milestone Payments 6/30/2010 7:34:33 AM
TargeGen, Inc. Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients 10/23/2009 8:17:42 AM
TargeGen, Inc. Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin 5/15/2009 8:49:14 AM
TargeGen, Inc. Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 American Society of Hematology Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients 12/2/2008 8:50:24 AM
Partnership Between Industry And Academia Has Led To Human Clinical Trials Of A New Drug; Stem Cell Research Leads To Potential New Therapy For Rare Blood Disorder 4/10/2008 8:12:41 AM
TargeGen, Inc. Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2/1/2008 7:29:10 AM
TargeGen, Inc. Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 12/7/2007 6:31:02 AM
TargeGen, Inc. Initiates Multi-Center Phase II Clinical Trial Of TG100801, a Topically Applied Kinase Inhibitor In Macular Degeneration Patients 7/30/2007 12:41:11 PM
TargeGen, Inc. Closes $40M Series 'D' Financing Round 7/12/2007 11:05:48 AM
TargeGen, Inc. Receives 2007 James D. Watson Helix Award in the Private Company Category 5/9/2007 12:06:53 PM
1234
//-->